Prostate Cancer Features Archive

The Psychological Impact of Prostate Cancer

The Psychological Impact of Prostate Cancer

Patients diagnosed with prostate cancer often struggle with their diagnosis.

Simpler Prostate Cancer Grading System Proposed

Simpler Prostate Cancer Grading System Proposed

Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.

Recent Developments in Prostate Cancer Management

Recent Developments in Prostate Cancer Management

Additional novel medical therapies to treat prostate cancer and earlier use of the existing medical therapies are the future of prostate cancer management.

Important Prostate Cancer Advances of the Last 10 Years

Important Prostate Cancer Advances of the Last 10 Years

Advances in prostate cancer screening, management and therapeutics have vastly improved patient care.

Statins Promising for Cancers

Statins Promising for Cancers

Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.

Prostate Cancer Genetics: Ready for Clinical Use?

Prostate Cancer Genetics: Ready for Clinical Use?

For decades, prostate cancer risk (PCa) stratification was based primarily on the architectural pattern of the tumor.

Nutrition Advice Challenged — Again

Nutrition Advice Challenged — Again

Human beings are unique in the animal kingdom when it comes to nutrition.

Sidestepping Sepsis via TP Biopsy: Interview with Jeremy Grummet, MBBS

Sidestepping Sepsis via TP Biopsy: Interview with Jeremy Grummet, MBBS

Rising readmission rates of subsequent sepsis have given urologic surgeon Jeremy Grummet, MBBS, MS, FRACS, pause.

Personalized Medicine in 2014

Personalized Medicine in 2014

The term "personalized medicine" remains an overused promise to apply specific treatment plans.

PCA3: What Is Its Role in Prostate Cancer Screening?

Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.

PCa Control Similar with RT, Radical Surgery: Interview with Frank Critz, MD

PCa Control Similar with RT, Radical Surgery: Interview with Frank Critz, MD

Some may find it surprising that Dr. Critz generally considers RP to be the go-to treatment for localized disease.

New Ablative Techniques in Urologic Oncology

Innovative approaches offer the potential for effective treatments to limited target 
areas with improved side effect profiles.

An Update on New Therapies for mCRPC: Interview with Oliver Sartor, MD

An Update on New Therapies for mCRPC: Interview with Oliver Sartor, MD

Radium-223 was approved in May 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease.

New Noninvasive Gold Standard for PCa Diagnosis: Interview With Vikram Dogra, MD

New Noninvasive Gold Standard for PCa Diagnosis: Interview With Vikram Dogra, MD

A nascent technology combines laser optics and ultrasound to distinguish between benign and malignant prostate tissue.

Another Nutritional Warning: Omega-3s

Another Nutritional Warning: Omega-3s

Once again, a study offers evidence that one of the keys to good nutrition is avoiding excess.

Managing Bone Loss Associated with Androgen Deprivation Therapy

While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.

Study Could Extend Survival Benefit of Provenge: Interview with Samir Khleif, MD

Study Could Extend Survival Benefit of Provenge: Interview with Samir Khleif, MD

Provenge is a breatkthrough treatment option for men with asymptomatic or minimally symptomatic metastatic, hormone-resistant PCa.

Reflections on the EAU Annual Congress

Reflections on the EAU Annual Congress

Having just returned from the always-stimulating European Association of Urology annual congress, I'd like to share a few impressions.

New Center for All-Around Prostate Cancer Treatment: Interview with Ashutosh Tewari, MB

New Center for All-Around Prostate Cancer Treatment: Interview with Ashutosh Tewari, MB

Ringing in the new year was especially exciting this time around for Ashutosh K. Tewari, MB, BS, head of the new Center for Prostate Cancer at New York-Presbyterian.

Current Controversies Surrounding PSA Screening

It is hoped that selective screening, selective biopsy, and selective therapy will 
further decrease the morbidity associated with screening.

Calcium for ADT Bone Loss May Worsen PCa: Interview with Gary Schwartz, PhD

Calcium for ADT Bone Loss May Worsen PCa: Interview with Gary Schwartz, PhD

Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.

An Update: Radiation or Surgery for Prostate Cancer

The management of patients with high-risk prostate cancer represents one of the ­biggest challenges today, with little consensus on optimal treatment.

Outlook Brightens for CRPC Patients

Outlook Brightens for CRPC Patients

In the past few years, urologists have seen some significant developments related to the treatment of metastatic castration-resistant prostate cancer (CRPC).

Optimal Sequencing for New Prostate Cancer Drugs: Interview with E. David Crawford, MD

Optimal Sequencing for New Prostate Cancer Drugs: Interview with E. David Crawford, MD

Several new drugs have become available for treating advanced prostate cancer in the past year and a half.

Prostate Cancer Screening: Moving Beyond PSA

Prostate Cancer Screening: Moving Beyond PSA

More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.

After Radical Prostatectomy, Patient Learns He Never Had Prostate Cancer

After Radical Prostatectomy, Patient Learns He Never Had Prostate Cancer

Dr. B, 57, was a urologist with a busy private practice. One of his patients was Mr. O, 69, who had an abnormal PSA result.

The Case for Brachytherapy: Interview with Michael Sarosdy, MD

The Case for Brachytherapy: Interview with Michael Sarosdy, MD

Having performed more than 1,200 brachytherapy treatments, Michael F. Sarosdy, MD, is convinced that this is a far better choice than surgery.

Highlights of the GU Cancers Symposium

Highlights of the GU Cancers Symposium

The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.

The Lowdown on HIFU: Interview with David Chen, MD

The Lowdown on HIFU: Interview with David Chen, MD

Although HIFU has not yet been approved in the US, a growing number of the nation's urologists are offering this noninvasive surgical procedure.

Examining the Pharmacoeconomics of Advanced Prostate Cancer

Examining the Pharmacoeconomics of Advanced Prostate Cancer

In determining prostate cancer treatment, physicians should discuss preferences, values, and expectations with patients, including life expectancy, adverse events, and costs

Intermittent ADT in Prostate Cancer: A Step-by-Step Approach

Intermittent ADT in Prostate Cancer: A Step-by-Step Approach

In select patients, use of intermittent therapy does not appear to negatively affect overall survival and is associated with fewer adverse events.

The Robotic Prostatectomy: Interview with Mani Menon, MD

The Robotic Prostatectomy: Interview with Mani Menon, MD

Mani Menon, MD, discusses the place of robotic prostatectomy in the treatment of localized prostate cancer.

Relationships of Testosterone and Prostate Cancer: A 2011 Perspective

Relationships of Testosterone and Prostate Cancer: A 2011 Perspective

A history of prostate cancer has generally been a contraindication for testosterone therapy, but the clinical model may be changing.

Managing Patients Following a Negative Prostate Biopsy

Managing Patients Following a Negative Prostate Biopsy

This article addresses the issues that must be understood to navigate the scenario posed by patients that have had a prior negative biopsy.

Repeat Prostate Biopsy Findings Often Not Benign

Prostate cancers diagnosed at repeat biopsy are as likely to be high grade as those found at initial biopsy, researchers reported in The Journal of Urology.

Sign Up for Free e-newsletters